Glycycoumarin is a potent antispasmodic agent. Glycycoumarin is a major bioactive coumarin of licorice and exhibits antispasmodic activity. Glycycoumarin also has hepatoprotective effect. Glycycoumarin can be used for the research of abdominal pain and liver diseases.
In Vitro
Glycycoumarin, (25 μM; 24 h) combining with ABT-737 (12.5 μM) synergistically, induces cell death in multiple types of liver cancer cell HepG2. Glycycoumarin is highly effective against alcoholic liver disease, nonalcoholic fatty liver disease, acetaminophen-induced hepatotoxicity, and liver cancer through mechanisms involved in activation of Nrf2 antioxidant system, stimulation of AMPK-mediated energy homeostasis, induction of autophagy degradation process, and inhibiting oncogenic kinase T-lymphokine-activated killer cell-originated protein kinase activity. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: HepG2, SMMC-7721, and Huh-7 Concentration: 10, 20, 25, 30, and 40 μM Incubation Time: 24 hours Result: Induced cell death in multiple types of liver cancer cell lines in a dose-dependent manner.
In Vivo
Glycycoumarin (30 μM-0.3 nM; 5 min) has an inhibitory effect on smooth muscle contraction induced by various types of stimulants through the inhibition of PDEs, especially isozyme 3, followed by the accumulation of intracellular cAMP .\nGlycycoumarin (10 mg/kg; i.p.; once daily for 4 d) enhances tumor growth inhibition in HepG2 xenograft model in mice and shows synergistical effect with ABT-737 . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male ICR mice (aged 6 weeks, weight 25-30 g) Dosage: 30 μM-0.3 nM, 5 min Administration: Result: Inhibited the contraction induced by various types of stimulants, such as CCh, KCI, BaCI(2), and A23187 (calcium ionophore III). Enhanced the relaxation induced by forskolin on CCh-evoked contraction and also enhances the relaxation effect of rolipram. Associated with dose-dependent accumulation of cAMP. Animal Model: HepG2 cancer cells xenograft model in male BALB/c athymic nude mice (6-7 weeks old)Dosage: 10 mg/kg Administration: Intraperitoneal injection; once daily for 4 days; ABT-737 group was given 100 mg/kg i.p. Result: Inhibited tumor growth and resulted a reduction of the final tumor weight by 17%.
Form:Solid
